Online inquiry

IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12572MR)

This product GTTS-WQ12572MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets Felcat NGF gene. The antibody can be applied in Feline osteoarthritis (OA) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Felinized
RefSeq XM_004001117.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 100144611
UniProt ID A0A337SBN0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-Felcat NGF, NV-02(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ12572MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ489MR IVTScrip™ mRNA-Anti-SELP, 42-89-glycoprotein(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA 42-89-glycoprotein
GTTS-WQ410MR IVTScrip™ mRNA-Anti-ANGPT2, 2xCon4C(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2xCon4C
GTTS-WQ14017MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ13459MR IVTScrip™ mRNA-Anti-ERBB2&TNFRSF9, PRS-343(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRS-343
GTTS-WQ14862MR IVTScrip™ mRNA-Anti-CD33, SGN-CD33A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-CD33A
GTTS-WQ8029MR IVTScrip™ mRNA-Anti-F, H1H3592P3(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA H1H3592P3
GTTS-WQ1150MR IVTScrip™ mRNA-Anti-VEGFA, ABP 215(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABP 215
GTTS-WQ12167MR IVTScrip™ mRNA-Anti-MSLN, MORAb-009(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MORAb-009
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW